$1.22
arrow_drop_down16.43%Performance History
| Key Stats | |
|---|---|
| Open | $1.32 |
| Prev. Close | $1.46 |
| EPS | -391.00 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $2.10M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.20 | 1.41 |
| 52 Week Range | 0.19 | 12.74 |
| Ratios | |
|---|---|
| P/B Ratio | 4.57 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | $0.00 |
| Earnings Growth % | -23.42% |
| EBITDA Margin % | - |
| ROEÂ % | -1,018.78% |
| EPS | -391.00 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
Correlated Companies
About CNS Pharmaceuticals (CNSP)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. John Michael Climaco Esq., J.D.
- Headquarters
- Houston
- Employees
- 3
- Exchange
- NASDAQ
Keep an eye on CNS Pharmaceuticals
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is CNS Pharmaceuticals 's (CNSP) price per share?
The current price per share for CNS Pharmaceuticals (CNSP) is $1.22. The stock has seen a price change of -$0.24 recently, indicating a -16.44% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for CNS Pharmaceuticals (CNSP)?
For CNS Pharmaceuticals (CNSP), the 52-week high is $12.74, which is 944.67% from the current price. The 52-week low is $0.19, the current price is 542.11% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is CNS Pharmaceuticals (CNSP) a growth stock?
CNS Pharmaceuticals (CNSP) has shown an average price growth of 0.41% over the past three years. It has received a score of -6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying CNS Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is CNS Pharmaceuticals (CNSP) stock price performance year to date (YTD)?
As of the latest data, CNS Pharmaceuticals (CNSP) has a year-to-date price change of -97.95%. Over the past month, the stock has experienced a price change of -77.37%. Over the last three months, the change has been -90.56%. Over the past six months, the figure is -97.95%.
Is CNS Pharmaceuticals (CNSP) a profitable company?
CNS Pharmaceuticals (CNSP) has a net income of -$18.85M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$18.87M. Furthermore, the EBITDA is -$17.48M.
What is the market capitalization of CNS Pharmaceuticals (CNSP)?
CNS Pharmaceuticals (CNSP) has a market capitalization of $2.11M. The average daily trading volume is 7.05M, indicating the stock's liquidity and investor engagement.
News
Top 5 Health Care Stocks That Are Preparing To Pump In February
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.